Pharmaceutics Technology Offers

Consejo Superior de Investigaciones Científicas posted this:

New antioxidant compounds: Polyphenols amide derivatives CSIC has synthetized and studied unknown polyphenolic compounds possessing high antioxidant activity, comparable and in some cases even higher than those of known natural polyphenols, as resveratrol and hydroxytyrosol. We are seeking for Pharmaceutical, Biotechnological, Food or Cosmetics companies interested in developing and marketing these compounds as drugs, cosmetics ingredients or dietary supplements under patent licensing. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Oleuropein obtaining procedure: high purity antioxidant CSIC has developed a reliable and effective method for obtaining oleuropein from olive leaf: comprising a pretreatment that increases the concentration of oleuropein in the extracts over other known methods and achieving this bioactive compound with a purity superior of 70%. Industrial partners from the food and pharmaceutical industry are being sought to collaborate through a patent licence agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Myt-healer: a new potent wound healing peptide CSIC and the University Miguel Hernández have developed a minimal peptide core from the M yti lus galloprovidencialis Myticin C peptide with unique in vitro and in vivo wound healing and regenerating activities. Industrial partners from the pharmaceutical and cosmetic industry are being sought to collaborate through a patent licence agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

OPTOBIOTICS: Novel antibacterial proteins activated by blue light CSIC has developed a chimeric protein that, when expressed in bacteria, changes its structure upon absorption of blue light, thus generating protein aggregates (amyloids) that inhibit bacterial growth Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement An offer for Patent Licensing

Ukrainian Laboratories posted this:

Computer aided drug discovery services Otava Research Institute helps researchers around the world develop advanced solutions for the variety of research projects maximizing their efficiencies, and, most of all, respecting their budgets. Our experts are involved in the development of leading compounds at any stage of the R&D process: starting from target identification to lead optimization

Ivan Rodriguez Rosello posted this:
Licensing Manager at Universidad de Alicante

Ultrasonic capillary reactor with temperature control and homogeneous vibration The Photochemistry and Semiconductor Electrochemistry (GFES) research group of the University of Alicante has developed an ultrasonically-enhanced capillary reactor which achieves homogeneous, efficient and temperature-controlled multiphase flow. The reactor features a capillary tube in a helicoidal probe that homogenizes the acoustic field generated without the appearance of longitudinal nodes and antinodes. Continuous and/or oscillatory reactions including crystallization phenomena are enabled, allowing the handling of solids and/or the improvement of heterogeneous mixtures in capillary tubes of variable diameter and length with optimum temperature control. Therefore, this reactor provides an advantage in flow chemistry and process intensification which is common in the pharmaceutical industry, fine chemistry, and in sonochemistry. The invention is protected by a patent application. The research group has a prototype on a laboratory scale. Companies interested in the commercial exploitation of this technology are sought through patent licensing agreements or technical cooperation agreements (R&D Projects).

Ivan Rodriguez Rosello posted this:
Licensing Manager at Universidad de Alicante

New multifunctional material for controlled-drug-release implants The "Advanced Materials" research group at the University of Alicante has developed a foamed material comprising three phases: a structural matrix, at least one host phase, and a fluid. This material is characterized by the fact that the structural matrix comprises a plurality of interconnected porous cavities, the host phase(s) is/are housed within at least one porous cavity of the structural matrix and the fluid is housed within the porous cavities. The host phase(s) can be housed within the porous cavities of the structural matrix without maintaining any union or maintaining discrete unions with the latter. The structural matrix may consist of a material of a metallic, polymeric, ceramic nature or mixtures thereof. Meanwhile, the host phase(s) is/are a functional material, the fluid being a liquid or a gas. These materials have many potential uses, among which ones is as an implant material, with the additional possibility of exerting a controlled release of drugs. Companies interested in commercial exploitation of this material through a patent license agreement are sought.

Ivan Rodriguez Rosello posted this:
Licensing Manager at Universidad de Alicante

New multifunctional material for catalysis applications The "Advanced Materials" research group at the University of Alicante has developed a foamed material comprising three phases: a structural matrix, at least one host phase, and a fluid. This material is characterized by the fact that the structural matrix comprises a plurality of interconnected porous cavities, the host phase(s) is/are housed within at least one porous cavity of the structural matrix and the fluid is housed within the porous cavities. The host phase(s) is/are housed within the porous cavities of the structural matrix without maintaining any bond with the latter. The structural matrix may consist of a material of a metallic, polymeric or ceramic nature or mixtures thereof. Meanwhile, the host phase(s) is/are a functional material, the fluid being a liquid or a gas. These materials have many potential uses, among which one is as a catalyst material or as a support for catalysts. Companies interested in the commercial exploitation of this material are sought through a patent license agreement.

Consejo Superior de Investigaciones Científicas posted this:

Overcoming resistance to Beta-lactam antibiotics in Bacterial species CSIC and the University of Würzburg have developed a new method to eliminate antibiotic-resistant bacterial infections using classical antibiotics previously discarded due the occurrence of antibiotic resistance. Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Purine derivatives for the treatment of neurodegenerative diseases CSIC has synthesized several substituted purine derivatives that are capable of inhibiting the activity of the CDC7 kinase. This inhibitory activity makes them useful for the treatment of neurological diseases. The compounds developed are, therefore, a new therapeutic alternative for Alzheimer's disease, amyotrophic lateral sclerosis or frontotemporal dementia. Industrial partners from pharmaceutical industry are being sought to develop and commercialized the compounds through a patent licence agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

New treatment for epidermolysis bullosa and fibrosis CSIC, Carlos III University of Madrid and CIEMAT have repositioned drugs that stimulate endogline expression and modulate the TGF-β route for a new clinical use in the treatment of fibrosis, such as epidermolysis bullosa (EB). EB includes a heterogeneous group of rare hereditary diseases of the skin in which in its infantile incidence the patients are known as "butterfly children". It is a new therapy for a rare pathology, with potential in a wide spectrum of fibrosis, which would improve the possibilities of treatment of patients, improving their quality of life. Industrial partners from the pharmaceutical industry are being sought for its development in a wide variety of fibrotic pathologies through a patent licence agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Control of neurodegenerative diseases with benzothiazole-benzamide derivatives Control of neurodegenerative diseases with benzothiazole-benzamide derivatives CSIC has developed a group of heterocyclic compounds derived from a privileged structural nucleus with the capacity to inhibit the LRRK2 enzyme. This inhibitory activity makes them useful in the treatment of neurodegenerative diseases affected by this enzyme, among which Parkinson's disease and Alzheimer's disease stand out. Pharmaceutical companies interested in the development and commercialization of these compounds under a patent license are sought. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Compounds for the treatment and prevention of immune-mediated inflammatory diseases CSIC and the University of Athens have found that secoiridoids, such as oleacein and oleocanthal, are useful to prevent or treat illnesses that results in immune-mediated gastrointestinal alterations. A company dealing with pharmaceutical or nutraceutical compositions is sought for licensing agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Biotechnological production of 11α hydroxylated steroids using recombinant bacteria.CSIC has developed a procedure for the biotechnological production of 11α hydroxylated steroids by generating and subsequent use of recombinant bacteria. These recombinant bacteria allow to perform microbial biotransformation processes that result in 11αhydroxylated steroid compounds from raw materials such as phytosterols and intermediate products efficiently and economically. These compounds have numerous applications in pharmacology. Companies are sought for implementing and commercializing the new technology under patent license agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Peptide for cancer control linked to IL13R R R α α 2 2 o o v v e e r r e e x x p p r r e e s s s s i i o o n n CSIC has developed a peptide capable of inhibiting the signaling of IL-13 mediated by IL13Rα2. This peptide alone or within a nanoparticle or virus-like particles can be used in a pharmaceutical composition for the treatment of pathologies in which IL13Rα2 is overexpressed. This composition would be useful in the treatment and control of metastasis of colon cancer and other tumors (i.e glioblastoma), as well as in other pathologies such as asthma, atopic dermatitis or fibrosis. Industrial partners are being sought to develop and commercialized the products through a patent licence agreement. An offer for Patent Licensing

Pharmaceutics Technology Offers

Innovation Resources

Sitemaps

Support

Company

Top Posts Categories

Recognitions

Pharmaceutics Technology Offers

Recognitions

Follow us